Clinical Trial Update: Study of Abiraterone Acetate and Prednisone in Combination With Cabazitaxel in Patients With Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating abiraterone acetate and prednisone in combination with cabazitaxel for prostate cancer was terminated; results were posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Abiraterone acetate (Zytiga) (abiraterone acetate)
• Cabazitaxel (Jevtana) (cabazitaxel)
• PREDNISONE (Prednisone)

Snippet

Sponsor: University of Colorado, Denver | Conditions: Prostate Cancer | Phase 2 | Status: TERMINATED | Results posted: 2018-06-04